Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217718383
Abstract: Patients with chronic lymphocytic leukemia with the 17p deletion have a poor prognosis and treatment options are limited. Venetoclax, a novel B-cell lymphoma-2 inhibitor, has been approved for treatment-experienced chronic lymphocytic leukemia patients with the… read more here.
Keywords: lymphocytic leukemia; novel cell; venetoclax novel; chronic lymphocytic ... See more keywords